U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone.
Protagonist Therapeutics, Inc. chose royalties over the original 50:50 U.S. profit-and-loss arrangement with Takeda Pharmaceutical Company Limited (NYSE:TAK). The April 2026 opt-out established tiered royalties of 14% to 29% on worldwide net sales and left Protagonist Therapeutics, Inc. eligible for up to $875 million of additional milestones. The structure trades commercial control and uncapped profit participation for approval-triggered, non-dilutive capital, lower execution risk, and a high royalty share.
Bull Case
The approval made another $275 million payable, in addition to the $849.5 million of cash, cash equivalents and marketable securities reported by Protagonist Therapeutics, Inc. as of June 30. The June balance already included the initial $200 million opt-out payment received during the second quarter.
The royalty structure is unusually favorable for a fully partnered medicine. The approximate 21% weighted-average rate disclosed by Protagonist Therapeutics, Inc. mechanically implies about $315 million of gross annual royalties at $1.5 billion of annual net sales, before contractual reductions and the separate obligation of Protagonist Therapeutics, Inc. to pay a third party a 1% royalty on worldwide rusfertide net sales. The top 29% tier applies to incremental annual net sales above $1.5 billion.
Takeda Pharmaceutical Company Limited holds exclusive worldwide development and commercialization rights and assumes the principal operating and financial responsibility. Protagonist Therapeutics, Inc. can therefore direct capital toward wholly owned programs without funding a commercial organization for MIMRYLO.
In the 293-patient Phase 3 VERIFY trial, 76.9% of patients receiving MIMRYLO plus current standard of care achieved the primary response endpoint during weeks 20 through 32, compared with 32.9% receiving placebo plus current standard of care. The endpoint measured the absence of phlebotomy eligibility. MIMRYLO also improved hematocrit control, phlebotomy burden, and fatigue measures.
Bear Case
Protagonist Therapeutics, Inc. no longer controls pricing, market access, launch sequencing, or commercial investment. Those decisions depend on execution by Takeda Pharmaceutical Company Limited. The 50:50 arrangement might have produced greater long-term economics if MIMRYLO becomes a major product, although Protagonist Therapeutics, Inc. would also have absorbed half of U.S. operating losses and commercialization costs.
The $875 million of potential additional milestones is contingent. International regulatory approvals, sales thresholds, and commercial execution must occur before much of that value becomes cash. Royalty payments may also be reduced under specified contractual circumstances.
MIMRYLO is a once-weekly subcutaneous treatment entering a market that includes phlebotomy and established cytoreductive therapies. The most common adverse reactions were injection-site reactions and anemia, and the label includes a warning for new or worsening thrombocytosis. Payer access and physician adoption will determine whether the headline royalty rates produce meaningful revenue.
Hedge Fund Sentiment
The filings available so far reflect positions held before Protagonist Therapeutics, Inc. reported FDA approval of MIMRYLO. Insider Monkey’s database showed 43 hedge funds holding Protagonist Therapeutics, Inc. at the end of 2Q2026, up from 42 funds three months earlier.
Conclusion
Partnering appears to be the better risk-adjusted commercial model for Protagonist Therapeutics, Inc.. The structure provides immediate non-dilutive capital, preserves substantial worldwide participation, and transfers most launch costs and execution risk to Takeda Pharmaceutical Company Limited. Whether it proves economically superior to the abandoned profit share remains unresolved. MIMRYLO must achieve broad access and durable adoption before the 14% to 29% royalties become a recurring cash-flow engine.
READ NEXT: Main Street Capital’s (MAIN) Blowout Exit Fuels A Bigger Dividend and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
This article is originally published at Insider Monkey.
Hedge Fund Resource Center